BAL PHARMA LTD. (BALPHARMA)

NSE: ₹87.11
BSE: ₹86.78
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

We are submitting the newspaper advertisements of the Audited financial results ( standalone & Consolidated ) for the quarter and financial year ended 31.03.2026 announced by the Company on 27.05.2026 and published in Financial express (English ) and Sanjayvani ( Kannada) on 29.05.2026.

2026-05-29 16:51:43
Non Applicability Of Statement Of Deviation & Variation

Filing of Statement of deviation & variation is not applicable to the Company for the quarter ended 31.03.2026.

2026-05-29 12:39:43
Audited Financial Results-Standalone & Consolidated

Audited financial results of the company for the quarter and financial year ended 31.03.2026.

2026-05-27 18:43:22
Board Meeting Outcome for Outcome Of The Board Meeting

Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend dividend of Rs1.20 per equity share of Rs.10 each i.e 12% 3.Appointed Cost Auditors and Internal auditors for the financial year 2026.27. 4. Approved grant of 5,00,000 stock options to the employees of the company under "Bal Pharma Ltd-Employee Stock Option Plan-2025" 5.Approved preferential issue of 10,00,000 warrants to the promoters. 6. Take shareholders approval for preferential issue through postal ballot. 7.Approved appointment of Mr.Shreepada M.L (M # A66681) as Company Secretary and compliance officer of the company.

2026-05-27 18:30:20
Announcement under Regulation 30 (LODR)-Meeting Updates

In addition to the agenda items mentioned in our board meeting notice dated 18.05.2025, the following agenda item will also be considered at the meeting scheduled on 27.05.2026. 1. To consider and approve proposal for fund raising through preferential issue of warrants to promoters. All other details and agenda items will remain unchanged. Please take this intimation on record.

2026-05-22 17:37:18
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for the financial year ended 31.03.2026.

2026-05-22 12:00:28
Board Meeting Intimation for Intimation Of The Board Meeting

1. Audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2. Audited standalone and consolidated accounts of the Company together with auditors report, for the F.Y ended 31.03.2026. 3. To recommend dividend if any, for the F.Y 2025.26. 4. To grant stock options to the employees of the Company under "Bal Pharma Ltd- Employee Stock Option Plan 2025"

2026-05-18 15:13:27
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

Intimation on resignation of Company Secretary & Compliance officer.

2026-05-12 11:27:11
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of SEBI(DP) Regulations, for the quarter ended 31.03.2026.

2026-04-06 12:41:05
Closure of Trading Window

Closure of Trading Window for the quarter and financial year ended 31.03.2026.

2026-03-23 12:46:18

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 70.17 92.30 81.49 94.58 73.13 74.70 72.89 81.78 65.64 73.75 87.49 83.92
YOY Revenue Growth % 0.94% 22.98% 6.44% 15.38% 4.22% -19.07% -10.56% -13.53% -10.25% -1.27% 20.04% 2.61%
Other Income 0.45 0.41 0.26 2.23 0.81 0.36 0.82 0.99 0.74 1.13 0.35 -0.22
Total Income 70.61 92.71 81.75 96.81 73.94 75.06 73.70 82.77 66.38 74.88 87.84 83.70
Total Expenses + 69.08 90.48 80.08 90.14 71.84 73.52 72.50 79.96 66.05 74.10 85.89 80.39
Cost of Materials Consumed 41.57 50.19 37.92 51.89 36.31 36.13 37.55 39.92 36.03 40.29 43.51 41.14
Employee Benefit Expense 13.20 14.18 14.17 14.56 13.84 14.88 14.81 15.35 14.67 16.15 17.19 17.92
Other Expenses 11.34 17.14 13.84 15.94 13.27 14.12 13.66 14.66 11.33 11.98 14.49 16.99
Operating Profit 1.08 1.82 1.42 4.44 1.29 1.18 0.38 1.82 -0.42 -0.35 1.60 3.53
OPM % 1.5% 2% 1.7% 4.7% 1.8% 1.6% 0.5% 2.2% -0.6% -0.5% 1.8% 4.2%
Profit Before Tax + 1.53 2.23 1.67 6.67 2.11 1.53 1.20 2.81 0.32 0.78 1.95 3.31
Tax Expense 0.34 0.63 0.42 0.45 0.36 0.32 0.05 -2.79 0.00 0.00 0.00 -0.39
Tax % 21.9% 28.2% 24.9% 6.8% 17% 20.8% 4% -99.3% 0% 0% 0% -11.7%
Profit After Tax 1.20 1.60 1.26 6.22 1.75 1.21 1.16 5.61 0.32 0.78 1.95 3.70
EPS (Basic) 0.76 1.02 0.80 4.16 1.11 0.76 0.73 3.51 0.20 0.49 1.22 2.60

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 310.80 302.50 338.54 303.10 280.37 249.31 170.67
YOY Revenue Growth % 2.74% -10.65% 11.69% 8.11% 12.46% 46.07% -
Other Income 2.00 2.15 3.35 2.15 6.49 2.70 3.62
Total Income 312.80 304.65 341.89 305.25 286.86 252.01 174.29
Total Expenses + 306.43 298.91 329.79 296.70 274.80 242.20 159.14
Cost of Materials Consumed 160.97 149.89 181.57 176.45 162.95 135.47 79.44
Employee Benefit Expense 65.92 61.83 56.11 51.91 44.46 39.62 48.77
Other Expenses 54.79 52.82 58.25 55.22 46.21 32.79 30.93
Operating Profit 4.36 3.58 8.75 6.39 5.57 7.10 11.53
OPM % 1.4% 1.2% 2.6% 2.1% 2% 2.8% 6.8%
Profit Before Exceptional 6.37 5.73 12.11 8.55 12.06 9.80 -9.57
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 6.37 5.73 12.11 8.55 12.06 9.80 -9.57
Tax Expense -0.39 -2.07 1.83 2.42 3.48 0.70 -0.04
Tax % -6.1% -36.1% 15.1% 28.3% 28.9% 7.1% -
Profit After Tax 6.75 7.80 10.27 6.13 8.57 9.10 -9.53
EPS (Basic) 4.27 4.89 6.72 3.90 5.79 6.41 -13.44

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 115.42 102.91 80.16 77.75 69.35 68.34 0.00
Property, Plant & Equipment 76.73 70.95 53.18 52.62 44.92 45.42 0.00
Capital Work in Progress 7.42 2.79 0.47 0.00 1.16 0.00 0.00
Non-Current Investments 2.16 2.16 9.58 0.00 0.00 8.40 0.00
Goodwill 3.83 3.83 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 13.42 12.00 11.38 10.45 7.98 7.23 0.00
Current Assets + 275.64 247.65 281.14 269.95 220.27 193.20 0.00
Inventories 116.13 102.78 87.49 97.69 73.97 60.12 0.00
Trade Receivables 96.36 94.85 103.10 94.84 77.91 69.44 0.00
Cash and Cash Equivalents 2.19 1.64 4.04 1.23 0.81 0.89 0.00
Current Investments 2.08 2.47 6.76 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 104.10 98.82 105.58 96.03 87.32 79.32 0.00
Equity Share Capital 15.92 15.92 15.80 15.69 14.82 14.82 0.00
Other Equity 88.18 82.90 89.78 80.34 72.50 64.50 0.00
Non-Current Liabilities 43.65 38.28 46.56 39.52 40.18 35.35 0.00
Current Liabilities 243.30 213.46 209.16 212.15 93.58 146.87 0.00
Total Liabilities 286.96 251.74 255.72 251.67 202.29 182.22 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities 8.82 20.31 33.35 -8.50 18.42 11.47 0.00
Cash from Investing Activities -26.82 -14.90 2.57 -17.95 30.76 0.00 0.00
Cash from Financing Activities -11.76 -7.83 24.21 0.00 0.00 -18.63 0.00
Net Increase/Decrease in Cash -28.45 -2.42 60.13 -26.45 49.18 -7.16 0.00